LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced positive Phase I data on the Company’s prostate cancer drug candidate CB7630 (abiraterone acetate). The data was presented last night during the poster session at the American Association for Cancer Research (AACR) Innovations in Prostate Cancer Research Conference that is currently taking place December 6-9, 2006 in San Francisco, CA.
